Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Gruber-Wackernagel, A; Bambach, I; Legat, FJ; Hofer, A; Byrne, SN; Quehenberger, F; Wolf, P.
Randomized double-blinded placebo-controlled intra-individual trial on topical treatment with a 1,25-dihydroxyvitamin D₃ analogue in polymorphic light eruption.
Br J Dermatol. 2011; 165(1):152-163
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Autor/innen der Med Uni Graz:
Gruber-Wackernagel Alexandra
Hofer Angelika
Legat Franz
Perchthaler Isabella
Quehenberger Franz
Wolf Peter
Altmetrics:

Dimensions Citations:

Plum Analytics:
Abstract:
Polymorphic light eruption (PLE) is a very frequent photodermatosis whose pathogenesis may involve resistance to ultraviolet (UV)-induced immune suppression. Similar to UV radiation, calcitriol (1,25-dihydroxyvitamin D₃) and its analogues such as calcipotriol have been shown to exhibit immunosuppressive properties. We performed a randomized double-blinded placebo-controlled intraindividual half-body trial (NCT00871052) to investigate the preventive effect of a calcipotriol-containing cream in PLE. Thirteen patients with PLE (10 women, three men; mean age 37 years) pretreated their skin on two symmetrically located test fields with calcipotriol or placebo cream twice daily for 7 days before the start of photoprovocation testing with solar-simulated UV radiation. We established a specific PLE test score [AA + SI + 0·4 P (range 0-12), where AA is affected area score (range 0-4), SI is skin infiltration score (range 0-4) and P is pruritus score on a visual analogue scale (range 0-10)] to quantify PLE severity. Photoprovocation led to PLE lesions in 12/13 (92%) patients. As shown by the PLE test score, compared with placebo calcipotrial pretreatment significantly reduced PLE symptoms in average by 32% (95% confidence interval 21-44%; P = 0·0022, exact Wilcoxon signed-rank test) throughout the observation period starting at 48 h until 144 h after the first photoprovocation exposure. At 48, 72 and 144 h calcipotriol pretreatment resulted in a lower PLE test score in 7 (58%), 9 (75%) and 10 (83%) of the 12 cases, respectively. Considering all time points together, calcipotriol diminished the PLE test score in all 12 photoprovocable patients (P = 0·0005; Wilcoxon signed-rank test). These results suggest a potential therapeutic benefit of topical 1,25-dihydroxyvitamin D₃ analogues as prophylactic treatment in patients with PLE. © 2011 The Authors. BJD © 2011 British Association of Dermatologists 2011.
Find related publications in this database (using NLM MeSH Indexing)
Administration, Topical -
Adult -
Aged -
Calcitriol - administration & dosage
Dermatitis, Photoallergic - pathology
Dermatitis, Photoallergic - prevention & control
Dermatologic Agents - administration & dosage
Dermatologic Agents - therapeutic use
Double-Blind Method -
Female -
Humans -
Male -
Middle Aged -
Prospective Studies -
Ultraviolet Rays - adverse effects
Vitamins - administration & dosage

© Meduni Graz Impressum